Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Myriad Genetics (0K3W) Share Price & Analysis

0 Followers

0K3W Stock Chart & Stats

$5.62-$0.24(-4.10%)
At close: 4:30 PM GMT
$3$4$5$6Aug 17Aug 31Sep 14Sep 28Oct 12Oct 26Nov 9
Day’s Range
$5.59 - $5.75
52-Week Range
$2.75 - $8.06
Previous Close
$5.86
Volume
N/A
Average Volume (3M)
16.41K
Market Cap
$542.92M
Enterprise Value
$514.77M
Total Cash (Recent Filing)
$107.10M
Total Debt (Recent Filing)
$209.40M
Price to Earnings (P/E)
―
Beta
-0.12
Next Earnings
Mar 02, 2027 (Est.)
EPS Estimate
-0.22
Last Dividend Ex-Date
Mar 15, 2022
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Strategic Focus And Liquidity

The planned Prenatal Health divestiture concentrates investment on Myriad’s Cancer Care Continuum, where management sees stronger long-term opportunities. Proceeds should also improve liquidity, enabling debt management, targeted growth investment, and greater resilience while the portfolio becomes more focused.

Hereditary Cancer Testing Demand

Record unaffected hereditary testing volume indicates durable demand beyond a narrow patient segment and supports the breadth of Myriad’s clinical offering. Continued commercial execution and a strong market position can help sustain adoption as genetic testing guidelines expand.

MRD Clinical And Commercial Potential

The interim Precise MRD data provides clinical support for a differentiated oncology diagnostic with potential to influence post-surgical monitoring. If reimbursement milestones are achieved, broader adoption could create a meaningful growth avenue within Myriad’s cancer-focused strategy.

Bears Say

Revenue Decline And Ongoing Losses

The sharp trailing revenue contraction and persistent operating and net losses show that Myriad has not yet converted strong gross margins into durable earnings. Continued losses can restrict reinvestment capacity and make execution of the focused growth strategy more financially demanding.

Negative Cash Generation

Negative operating and free cash flow indicate that the current business still consumes cash despite some improvement from earlier periods. Until operations consistently fund the company, Myriad remains more exposed to execution setbacks and has less internally generated flexibility for investment or debt reduction.

Reimbursement And Pricing Pressure

Rising authorization requirements, denials, and lower hereditary-testing revenue per test can pressure both demand economics and realized pricing. These reimbursement frictions may limit margin recovery and require continued revenue-cycle investment, even as testing volumes grow.

Myriad Genetics News

0K3W FAQ

What was Myriad Genetics’s price range in the past 12 months?
Myriad Genetics lowest share price was $2.75 and its highest was $8.06 in the past 12 months.
What is Myriad Genetics’s market cap?
Myriad Genetics’s market cap is $542.92M.
When is Myriad Genetics’s upcoming earnings report date?
Myriad Genetics’s next earnings report is estimated for Mar 02, 2027 (not yet confirmed), which is in 107 days.
How were Myriad Genetics’s earnings last quarter?
Myriad Genetics released its earnings results on Nov 04, 2026. The company reported -$0.11 earnings per share for the quarter, beating the consensus estimate of -$0.2 by $0.09.
Is Myriad Genetics overvalued?
According to Wall Street analysts Myriad Genetics’s price is currently Undervalued.
Does Myriad Genetics pay dividends?
Myriad Genetics pays a dividend of $0.285 which represents an annual dividend yield of ―. See more information on Myriad Genetics dividends here
What is Myriad Genetics’s EPS estimate?
Myriad Genetics’s EPS estimate is -0.22.
How many shares outstanding does Myriad Genetics have?
Myriad Genetics has 95,922,195 shares outstanding.
What happened to Myriad Genetics’s price movement after its last earnings report?
Myriad Genetics reported an EPS of -$0.11 in its last earnings report, beating expectations of -$0.2. Following the earnings report the stock price went up 3.232%.
Which hedge fund is a major shareholder of Myriad Genetics?
Hedge funds hold Myriad Genetics shares: the largest hedge-fund position in Myriad Genetics is 27,172,379 shares, and hedge funds decreased their holdings by 6.6M shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology